株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ハンチントン病治療の世界市場

Huntington's Disease Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 121147
出版日 ページ情報 英文 122 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
ハンチントン病治療の世界市場 Huntington's Disease Therapeutics
出版日: 2015年03月01日 ページ情報: 英文 122 Pages
概要

当レポートでは、世界のハンチントン病治療薬市場について調査し、業界の概要と動向、2014〜2020年の予測とともに、地域別動向、企業プロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 序論
    • 現在のハンチントン病治療
    • ハンチントン病:概要
    • 市場の機会
    • 主要地域/国におけるハンチントン病罹患率
    • 現在のハンチントン病管理戦略の有効性
    • 治療法と薬剤
    • 代替治療
    • 未承認の処方薬
  • 市場動向
  • ハンチントン病パイプライン分析
  • ハンチントン病分野における画期的研究
  • ハンチントン病の概要
    • イントロダクション
    • 歴史的背景
    • 予後
    • 病期
    • 症状と徴候
    • ハンチントン病の遺伝学
    • ハンチントン病の診断
    • ハンチントン病の診断検査
    • 治療法
  • 近年の業界活動
  • 主要企業
    • Alnylam Pharmaceuticals, Inc.
    • Auspex Pharmaceuticals, Inc.
    • Intellect Neurosciences Incorporation
    • Lundbeck A/S
    • Prana Biotechnology Limited
    • Raptor Pharmaceuticals Corp.
    • Sangamo Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd
    • Trophos SA
    • Valeant Pharmaceuticals International, Inc.
    • Vertex Pharmaceuticals Incorporated
  • 世界市場見通し

第3章 市場

  • 米国
  • 欧州
    • フランス
    • ドイツ
    • 英国
    • スペイン
  • その他の諸国

第4章 競合環境

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6280

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

Alnylam Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc.
Intellect Neurosciences Incorporation
Lundbeck A/S
Prana Biotechnology Limited

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Prelude
  • Current HD Treatment
  • Huntington's Disease - Quick Facts
  • Market Opportunity
  • Huntington's Disease Prevalence in Major Region/Countries
  • Competition in the Global HD Therapeutics Market is Non-existent
  • Effectiveness of Current HD Management Strategies
  • HD Treatment and Drugs: Brief Description of Disorder, Medication and Side-Effects
  • Alternative Treatment Approaches for Huntington's Disease
  • Alternate Approaches and Therapies
  • Off-Label Prescriptions
  • Select Off-Label Drugs Prescribed for Huntington's Disease: Drug Name & Manufacturer; Treatment Class; and Primary Indication
  • mHtt Aggregates in HD-Molecular Pathogenesis

2. HD THERAPEUTICS MARKET TRENDS

  • Therapeutics Focus on Reduction of mHtt Expression
  • Companies Boost R&D Spending for HD Therapeutics
  • Improved Diagnostics Fueling Interest of Companies in HD Research
  • Support Organizations Play an Instrumental Role in HD Research and Awareness
  • Public-Private Partnerships: A Shot in the Arm
  • HD Research Attracts 'Big Pharma' Investment
  • Pre-Symptomatic Patients to Expand Market Base
  • HDSA Pushes for Improvement in Medicare Funding for Huntington's Disease
  • GINA for Reducing Discrimination Faced by People with HD

3. HUNTINGTON'S DISEASE PIPELINE ANALYSIS

  • A Quick Primer
  • Drug Development Pipeline Reveals a Promising Picture
  • Select Drugs and Supplements in HD Research Pipeline (2014): Drug Name, Manufacturer, Mode of Action and Current Status
  • An Overview of Select Drugs in Late-Stage Clinical Trials
  • SD-809
  • RP103 (Procysbi)
  • PBT2
  • Huntexil(tm) (Pridopidine)
  • Other Novel Approaches for HD Treatment
  • Cellular Delivery of Neurotropic Agents
  • Cogane
  • COPREXA
  • Histone Deacetylases (HDAC)
  • Melatonin, Coenzyme Q-Free Radical Scavengers
  • RNAi - RNA Interference

4. RESEARCH BREAKTHROUGHS IN HD ARENA

  • Triglyceride Oil 'Triheptanoin' Shows Promise for HD Therapeutics
  • Reducing mTORC1 Activation through Drug/Diet May be Helpful
  • Better Understanding of Early Neuronal Changes Lead to Targeted Drug Development
  • Lund University Researchers Successfully Map Functionality of Hypothalamus in HD
  • MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on KMO Enzyme
  • Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease Progression in Patients
  • Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of Huntington's Disease on Human Brain
  • Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of HD
  • Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in HD Patients
  • University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy Potential for Treating HD
  • NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing Progress of HD
  • Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD Symptoms
  • Development of HD Affected Human Brain Cells for Investigative Purposes
  • Device Implant in Brain Exhibits Therapeutic Potential for HD
  • Sangamo Biosciences on Path to Discover a Therapy for HD
  • Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10 for Reduction of Oxidative Damage in HD Patients

5. AN OVERVIEW OF HUNTINGTON'S DISEASE

  • Introduction
  • Historical Background
  • Prognosis
  • Stages of HD
  • Symptoms and Signs
  • Physical Symptoms
  • Emotional Symptoms
  • Mental Symptoms
  • Genetics of Huntington's Disease
  • Inheritance
  • Mechanism
  • Functions of HTT
  • Effects of mHTT on Cells
  • Macroscopic Effects of mHTT
  • Diagnosis of HD
  • Clinical Diagnosis
  • Embryonic Diagnosis
  • Differential Diagnosis
  • Diagnostic Tests for Huntington's Disease
  • Confirmatory Diagnostic Test
  • Pre-symptomatic Diagnostic Test
  • Prenatal Diagnostic Test
  • Treatment Options
  • Nutrition and Eating
  • Social Activity
  • Speech Therapy
  • Physical Therapy
  • Occupational Therapy
  • Medication
  • Molecular Chaperones

6. RECENT INDUSTRY ACTIVITY

  • Auspex Reports Favorable Study Results of SD-809
  • Sangamo and Collaborators to Present ZFP Therapeutics(r) Data
  • Sangamo Presents Positive Preclinical Data of ZFP Therapeutic(r)
  • Sangamo BioSciences Acquires Ceregene
  • Prana Completes Reach2HD Trial
  • Teva Pharmaceuticals Forms Global R&D Collaboration for HD
  • KineMed, Isis and CHDI Foundation Collaborate for HD Therapeutics
  • CHDI Foundation Continues Collaboration with Medtronic
  • Roche Enters into Alliance with Isis Pharmaceuticals
  • Omeros Receives IND Approval for OMS824 for Huntington's Disease
  • Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch
  • uniQure and Benitec Biopharma Ink Cross-Licensing Agreement
  • Evotec and CHDI Foundation Extend Collaboration
  • Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds
  • GNS Healthcare Enters into Collaboration with CHDI Foundation
  • Lundbeck Collaborates with CHDI Foundation for HD Research
  • Horizon Discovery Collaborates with Institute of Neurology, London
  • Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership

7. FOCUS ON SELECT PLAYERS

  • Alnylam Pharmaceuticals, Inc. (US)
  • Auspex Pharmaceuticals, Inc. (US)
  • Intellect Neurosciences Incorporation (US)
  • Lundbeck A/S (Denmark)
  • Prana Biotechnology Limited (Australia)
  • Raptor Pharmaceuticals Corp. (US)
  • Sangamo Biosciences, Inc. (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Trophos SA (France)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Vertex Pharmaceuticals Incorporated (US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 1: World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 2: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 3: World 12-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • HDSA Brings about Improved Medicare Funding for Huntington's Disease
    • GINA for Reducing Discrimination Faced by People with HD
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 4: The US Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 5: The US Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2. EUROPE

  • Market Analysis
    • Table 6: European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 7: European Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 8: European 12-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, UK, Spain and Rest of Europe Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

2a. FRANCE

  • A. Market Analysis
    • Trophos Sa - A Key Player
  • B. Market Analytics
    • Table 9: French Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 10: French Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 11: German Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 12: German Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2c. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Table 13: Juvenile HD Incidence Estimates in the UK(includes corresponding Graph/Chart)
    • Table 14: Juvenile HD Prevalence Estimates in the UK (2006-2010) (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 15: The UK Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 16: The UK Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2d. SPAIN

  • A. Market Analysis
    • KEY PLAYER - SOM BIOTECH
  • B. Market Analytics
    • Table 17: Spanish Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 18: Spanish Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2e. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 19: Rest of Europe Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 20: Rest of Europe Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

3. REST OF WORLD

  • A. Market Analysis
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 21: Rest of World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 22: Rest of World Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

  • Total Companies Profiled: 25 The United States (13) Canada (1) Europe (8) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (3)

COMPETITIVE LANDSCAPE

Back to Top